Literature DB >> 23465200

Taming systems to create enabling environments for HCV treatment: negotiating trust in the drug and alcohol setting.

Magdalena Harris1, Tim Rhodes, Anthea Martin.   

Abstract

HCV (hepatitis C) treatment uptake among the population most affected - people who inject drugs - is suboptimal. Hospital based treatment provision is one evidenced barrier to HCV treatment uptake. In response, HCV treatment is increasingly located in treatment settings seen as more amenable to people who inject drugs, such as drug and alcohol services. We explored the accessibility of HCV treatment provision at two such partnerships. Data collection comprised qualitative interviews collected in 2011 and 2012 with 35 service users and 14 service providers of HCV treatment in London, United Kingdom. We draw here primarily on thematic analyses of service provider accounts, yet narratives relating to trust and environment emerged unsolicited in both user and provider accounts of negotiated HCV treatment access. A key theme in service provider accounts were strategies they deployed to 'tame' the treatment system so as to create an 'enabling environment' of care, in which trust was a critical feature. This 'taming' of the system was enacted through practices of 'negotiated flexibility', including in relation to appointments, eligibility, and phlebotomy. Service user accounts accentuated familiar environments and known health providers as those most trusted, and the potentially stigmatising effects of negotiating treatment in unfamiliar territory, especially hospital settings. Whilst noting the effects of provider strategies to negotiate flexibility on behalf of would-be patients seeking treatment, we conclude by noting the limits of trust relations in settings of constrained choice.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23465200     DOI: 10.1016/j.socscimed.2013.01.031

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  22 in total

1.  Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis.

Authors:  Jason Grebely; Lucy Tran; Louisa Degenhardt; Alexander Dowell-Day; Thomas Santo; Sarah Larney; Matthew Hickman; Peter Vickerman; Clare French; Kerryn Butler; Daisy Gibbs; Heather Valerio; Phillip Read; Gregory J Dore; Behzad Hajarizadeh
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

2.  An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential.

Authors:  David C Perlman; Ashly E Jordan; Anneli Uuskula; Duong Thi Huong; Carmen L Masson; Bruce R Schackman; Don C Des Jarlais
Journal:  Int J Drug Policy       Date:  2015-04-27

3.  Generating trust: Programmatic strategies to reach women who inject drugs with harm reduction services in Dar es Salaam, Tanzania.

Authors:  Sophia Zamudio-Haas; Bathsheba Mahenge; Haneefa Saleem; Jessie Mbwambo; Barrot H Lambdin
Journal:  Int J Drug Policy       Date:  2016-01-23

4.  Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.

Authors:  Jason Grebely; Julie Bruneau; Jeffrey V Lazarus; Olav Dalgard; Philip Bruggmann; Carla Treloar; Matthew Hickman; Margaret Hellard; Teri Roberts; Levinia Crooks; Håvard Midgard; Sarah Larney; Louisa Degenhardt; Hannu Alho; Jude Byrne; John F Dillon; Jordan J Feld; Graham Foster; David Goldberg; Andrew R Lloyd; Jens Reimer; Geert Robaeys; Marta Torrens; Nat Wright; Icro Maremmani; Brianna L Norton; Alain H Litwin; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2017-07-03

Review 5.  Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors.

Authors:  Magdalena Harris; Tim Rhodes
Journal:  Harm Reduct J       Date:  2013-05-07

6.  "Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs.

Authors:  Trevor Goodyear; Helen Brown; Annette J Browne; Peter Hoong; Lianping Ti; Rod Knight
Journal:  Int J Drug Policy       Date:  2021-04-23

7.  Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion.

Authors:  Carissa E Chu; Feng Wu; Xi He; Kali Zhou; Yu Cheng; Weiping Cai; Elvin Geng; Paul Volberding; Joseph D Tucker
Journal:  Open Forum Infect Dis       Date:  2016-06-24       Impact factor: 3.835

Review 8.  Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals.

Authors:  Zachary C Rich; Carissa Chu; Jessica Mao; Kali Zhou; Weiping Cai; Qingyan Ma; Paul Volberding; Joseph D Tucker
Journal:  BMC Public Health       Date:  2016-09-20       Impact factor: 3.295

9.  Harm Reduction and Tensions in Trust and Distrust in a Mental Health Service: A Qualitative Approach.

Authors:  Rozilaine Redi Lago; Elizabeth Peter; Cláudia Maria Bógus
Journal:  Subst Abuse Treat Prev Policy       Date:  2017-03-08

10.  Treatment trajectories and barriers in opioid agonist therapy for people who inject drugs in rural Puerto Rico.

Authors:  Roberto Abadie; Katherine McLean; Patrick Habecker; Kirk Dombrowski
Journal:  J Subst Abuse Treat       Date:  2021-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.